This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Antiplatelet Drugs - Do We Need New Options? With a Reappraisal of Direct Thromboxane Inhibitors

Published 2010 in Unknown venue

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2010
Venue
Unknown venue
Publication date
Unknown publication date
Fields of study
Medicine
Identifiers
No identifiers available.
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Cardiovascular risk assessment in Italy: the CUORE Project risk score and risk chart
2024cited by this paper
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes
2012cited by this paper
Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus
2012cited by this paper
Clinical implications of clopidogrel non‐response in cardiovascular patients: a systematic review and meta‐analysis
2010cited by this paper
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
2010cited by this paper
Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism.
2010cited by this paper
Response to Letter Regarding Article, “Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization”
2010cited by this paper
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
2010cited by this paper
Aspirin, 110 years later
2009cited by this paper
A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study
2009cited by this paper
Aspirin Use, Dose, and Clinical Outcomes in Postmenopausal Women With Stable Cardiovascular Disease: The Women’s Health Initiative Observational Study
2009cited by this paper
Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding
2009cited by this paper
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
2009cited by this paper
Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance
2009cited by this paper
Platelet inhibition with cangrelor in patients undergoing PCI.
2009cited by this paper
Genetic determinants of response to clopidogrel and cardiovascular events.
2009cited by this paper
Influence of statin treatment on platelet inhibition by clopidogrel – a randomized comparison of rosuvastatin, atorvastatin and simvastatin co‐treatment
2009cited by this paper
Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.
2009cited by this paper
Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting
2009cited by this paper
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
2009cited by this paper
Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking “Paradox”
2009cited by this paper
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
2009cited by this paper
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.
2009cited by this paper
Variability in responsiveness to oral antiplatelet therapy.
2009cited by this paper
Cytochrome p-450 polymorphisms and response to clopidogrel.
2009cited by this paper
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial
2009cited by this paper
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
2009cited by this paper
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
2009cited by this paper
Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
2009cited by this paper
Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg)
2009cited by this paper
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
2009cited by this paper
Facts and controversies of aspirin and clopidogrel therapy.
2009cited by this paper
New P2Y12 blockers
2009cited by this paper
Combining antiplatelet and anticoagulant therapies.
2009cited by this paper
Advances in antiplatelet therapy: agents in clinical development.
2009cited by this paper
Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery.
2009cited by this paper
Intravenous platelet blockade with cangrelor during PCI.
2009cited by this paper
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
2009cited by this paper
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
2009cited by this paper
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.
2009cited by this paper
Aspirin for Prevention and Treatment of Cardiovascular Disease
2009cited by this paper
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
2009cited by this paper
[Study of variability in response to aspirin and clopidogrel: clinical and/or biological resistance?].
2009cited by this paper
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
2009cited by this paper
Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
2009cited by this paper
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
2009cited by this paper
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
2009cited by this paper
Beyond glucose levels in diabetic patients with coronary artery disease: Platelet activity and non-responsiveness to antiplatelet therapy
2008cited by this paper
Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease
2008cited by this paper
Calcium channel blockers reduce the antiplatelet effect of clopidogrel
2008cited by this paper
Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
2008cited by this paper
Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
2008cited by this paper
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
2008cited by this paper
Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA: A Meta-Analysis
2008cited by this paper
Aspirin for primary prevention of cardiovascular events in diabetes: still an open question.
2008cited by this paper
Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis
2008cited by this paper
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
2008cited by this paper
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial
2008cited by this paper
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel
2008cited by this paper
The role of aspirin in cardiovascular prevention: implications of aspirin resistance.
2008cited by this paper
Letter by Klein Regarding Article, "Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study"
2008cited by this paper
The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid
2008cited by this paper
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
2008cited by this paper
asymptomatic peripheral arterial disease and antioxidants in patients with diabetes and randomised placebo controlled trial of aspirin factorial disease and diabetes (POPADAD) trial: The prevention of progression of arterial
2008cited by this paper
Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
2008cited by this paper
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
2008cited by this paper
Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome.
2008cited by this paper
Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis.
2008cited by this paper
Clinical ResearchInterventional CardiologyPoint-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reacti
2008cited by this paper
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100
2007cited by this paper
A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
2007cited by this paper
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
2007cited by this paper
Evidence that pre‐existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’
2007cited by this paper
Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease
2007cited by this paper
Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double‐blind trial
2007cited by this paper
A review of picotamide in the reduction of cardiovascular events in diabetic patients
2007cited by this paper
Platelet activation and atherothrombosis.
2007cited by this paper
Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study
2007cited by this paper
A critical review of antiplatelet treatment in peripheral arterial disease
2007cited by this paper
Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis.
2007cited by this paper
Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia
2006cited by this paper
The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
2006cited by this paper
Preclinical Evaluation of S18886 in an Experimental Model of Coronary Arterial Thrombosis
2006cited by this paper
Aspirin to prevent heart attack and stroke: what's the right dose?
2006cited by this paper
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
2006cited by this paper
Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials
2006cited by this paper
Mechanism of action of novel NO‐releasing furoxan derivatives of aspirin in human platelets
2006cited by this paper
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.
2006cited by this paper
Prévention des évènements ischémiques majeurs au cours de l’artériopathie oblitérante des membres inférieurs : l’aspirine a-t-elle un rôle ?
2006cited by this paper
Aspirin Resistance
2006cited by this paper
Does pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition of platelet function? In vitro experience.
2006cited by this paper
Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
2006cited by this paper
Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism
2005cited by this paper
Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke.
2005cited by this paper
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice
2005cited by this paper
Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study.
2005cited by this paper
Cyclooxygenase‐1 haplotype modulates platelet response to aspirin
2005cited by this paper
Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin
2005cited by this paper
Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study*
2005cited by this paper
Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial
2005cited by this paper

CITED BY

Synthesis, and docking studies of arylhydrazone compounds and evaluation of their platelet aggregation inhibitory effect and cytotoxicity
2022cites this paper
QSAR Study of Some Natural and Synthetic Platelet Aggregation Inhibitors and their Pharmacological Profile
2022cites this paper
Altered distribution of adrenergic constrictor responses contributes to skeletal muscle perfusion abnormalities in metabolic syndrome
2017cites this paper
Altered Distribution of Adrenergic Constrictor Responses Contributes to Skeletal Muscle Perfusion Abnormalities in Metabolic Syndrome
2017cites this paper
Inhibition of platelet aggregation and thrombosis by indole alkaloids isolated from the edible insect Protaetia brevitarsis seulensis (Kolbe)
2016cites this paper
Atherosclerotic Coronary Artery Disease
2015cites this paper
Synthesis of N-arylmethyl Substituted Indole Derivatives as New Antiplatelet Aggregation Agents
2014cites this paper
Platelets and their chemokines in atherosclerosis—clinical applications
2014cites this paper
CASE OF VERY LATE STENT THROMBOSIS AFTER DISCONTINUATION OF DUAL ANTIPLATELET THERAPY
2013cites this paper
Emerging targets in lipid-based therapy.
2013cites this paper
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update.
2012cites this paper
Antiplatelet Activity of the Antihypertensive Agent Losartan In Vivo Characterization
2012cites this paper
Ischemic stroke in patients receiving aspirin.
2012cites this paper
Characterization of the In Vivo Antiplatelet Activity of the Antihypertensive Agent Losartan
2012cites this paper
Thromboxane A2 Receptor
2012cites this paper
Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline
2011cites this paper
Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention
2011cites this paper
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition
2011cites this paper
Platelets in atherosclerosis
2011cites this paper